The Efficacy of Paxman Scalp Cooling System in Preventing Hair Loss in Breast Cancer Patients Receiving Chemotherapy in Western India - Multi-centre Retrospective Cohort Study.

Autor:	Mekha M; From the Department of Medical Oncology, Mumbai Oncocare Centre, Pune, India., Joshi A; Department of Medical Oncology, Mumbai Oncocare Centre, Mumbai, India., Maniar V; Department of Medical Oncology, Mumbai Oncocare Centre, Mumbai, India., Maheshwari U; Department of Medical Oncology, Mumbai Oncocare Centre, Mumbai, India., Joshi K; Department of Medical Oncology, Mumbai Oncocare Centre, Mumbai, India., Kalaskar P; Department of Medical Oncology, Mumbai Oncocare Centre, Mumbai, India., Sheth S; Department of Medical Oncology, Mumbai Oncocare Centre, Mumbai, India., Kendre P; Department of Medical Oncology, Mumbai Oncocare Centre, Mumbai, India., Morzaria D; Department of Clinical Research, Mumbai Oncocare Centre, Mumbai, India., Korgavkar R; Department of Clinical Research, Mumbai Oncocare Centre, Mumbai, India., Pethe C; Department of Medical Oncology, Mumbai Oncocare Centre, Nashik, India., Dhande S; Department of Medical Oncology, Mumbai Oncocare Centre, Nashik, India.
Jazyk:	angličtina
Zdroj:	Indian journal of dermatology [Indian J Dermatol] 2024 Jan-Feb; Vol. 69 (1), pp. 16-23. Date of Electronic Publication: 2024 Feb 27.
DOI:	10.4103/ijd.ijd_345_23
Abstrakt:	Aim: Chemotherapy-induced alopecia (CIA) is the most common side effect of systemic treatment in breast cancer patients. Scalp cooling gained worldwide acceptance in preventing or mitigating CIA in patients undergoing chemotherapy. The objective of this study was to evaluate the efficacy and safety of the Paxman scalp cooling system (PSCS) in Indian breast cancer patients. Materials and Methods: This is a multi-centre, retrospective-observational study including patients registered from 1 st March, 2019 to 30 th April, 2021 undergoing chemotherapy for breast cancer by using PSCS. The primary end-point was the incidence of CIA after completing cycles of chemotherapy. Results: A total of 91 female patients were enrolled in the study, with a median age of 53 years (IQR: 44-62 years). The prevention of alopecia (grade 0 and grade I) was seen in 81%, while more than 50% hair loss (grade 2) was seen in 16.48% after completion of treatment. The univariate analysis results showed that CIA was significantly higher in patients who received anthracyclines (OR: 2.69; 95% CI: 1.04-6.958; P = 0.041) and in patients with a post-infusion cooling time of >150 minutes (OR: 8.409; 95% CI: 2.295-30.787; P = 0.001). The incidence of grade 2 (>50% hair loss) alopecia was 81.3% in patients <6 weeks and was 18.8% at >6 weeks of start of chemotherapy ( P < 0.0001). No adverse events were reported in 71.4% of patients, and the most common adverse event was headache (18.7%). Conclusion: PSCS is an effective and well-tolerated treatment modality for preventing CIA among breast cancer patients undergoing chemotherapy. Competing Interests: There are no conflicts of interest. (Copyright: © 2024 Indian Journal of Dermatology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF